Clinical Trials Directory

Trials / Completed

CompletedNCT03825380

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
485 (actual)
Sponsor
Laboratoires Thea · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

Conditions

Interventions

TypeNameDescription
DRUGBimatoprostEyedrops
DRUGLumigan®Eyedrops

Timeline

Start date
2018-11-23
Primary completion
2021-02-03
Completion
2021-02-24
First posted
2019-01-31
Last updated
2023-11-21
Results posted
2023-11-21

Locations

1 site across 1 country: Estonia

Source: ClinicalTrials.gov record NCT03825380. Inclusion in this directory is not an endorsement.

Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients (NCT03825380) · Clinical Trials Directory